featured-image

NASDAQ | TSX: ACB , /PRNewswire/ - Aurora Cannabis Inc. (the or ) (NASDAQ: ) (TSX: ACB), a leading -based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2024. As the fiscal year 2023 consisted of three quarters, the year-over-year comparison quarter for Q4 2024 ending is Q3 2023 ending .

"We are incredibly pleased to be reporting our strongest fiscal year ever at Aurora. Total fiscal year 2024 net revenue increased 21% compared to the trailing four quarters, while adjusted EBITDA was positive on an annualized basis for the first time in our history, reaching . We also strengthened our balance sheet, ending with a strong net cash position of approximately as of , and fully repaid our convertible debt," said Chief Executive Officer .



"Aurora is the largest global medical cannabis company in nationally legal markets and our leadership is best differentiated by serving the diverse needs of patients across the world. In Q4 2024, global medical cannabis net revenue increased 20% year-over-year, supported by the recent acquisition of MedReleaf Australia, where we saw significant growth, along with higher sales in and the UK. We also achieved our highest quarterly adjusted gross margin in medical cannabis of 66%, far ahead of our targeted range of 60%.

These results are encouraging as we continue to progress towards our next milestone of positive free cash flow by " concluded Mr. Martin. Total net revenue .

Back to Health Page